Condition: Malignant Solid Tumors · Sponsor: Takeda
Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable). This study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorectal cancer or CRC), lung cancer (non-small lung cell cancer or NSCLC) and cancer in the mouth, throat or voice box (head and neck squamous cell carcinoma or HNSCC). The main aims of this study are to learn how safe TAK-505 is, how well it works, how well adults with solid tumors tolerate it and to find the dose of TAK-505 that works best with the least side effects. Other aims are to learn how TAK-505 moves through the body (pharmacokinetics (PK)), if it can shrink or slow cancer (preliminary antitumor activity) and to find out if it causes the body's defense system to react to it (immunogenicity).
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| UCI Health | Orange, California, United States | Not Yet Recruiting |
| University of California San Diego Medical Center, La Jolla | San Diego, California, United States | Not Yet Recruiting |
| University of California San Francisco | San Francisco, California, United States | Not Yet Recruiting |
| H Lee Moffitt Cancer Center | Tampa, Florida, United States | Not Yet Recruiting |
| Univeristy of Minnesota | Minneapolis, Minnesota, United States | Not Yet Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Not Yet Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Not Yet Recruiting |
| Sarah Cannon Research Institute SCRI | Nashville, Tennessee, United States | Not Yet Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Not Yet Recruiting |
| Mary Crowley Cancer Center | Dallas, Texas, United States | Not Yet Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Not Yet Recruiting |
| MD Anderson | Houston, Texas, United States | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07436728